LOGIN  |  REGISTER
Cue Biopharma
Compass Therapeutics

Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2024 Results on April 18, 2024

April 03, 2024 | Last Trade: US$314.89 8.14 2.65

INDIANAPOLIS / Apr 03, 2024 / Business Wire / Elevance Health (NYSE: ELV) will release first quarter 2024 financial results on April 18, 2024, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

  • 888-947-9963 – Access Code - 3972058 (Domestic)
  • 312-470-0178 – Access Code - 3972058 (International)
  • 800-876-4955 – No Access Code (Domestic Replay)
  • 203-369-3997 – No Access Code (International Replay)

The replay will be available from 11:30 a.m. EDT on April 18, 2024, until the end of the day on May 17, 2024. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. You may also access the webcast here. A webcast replay will be available following the call.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 115 million consumers through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page